Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 615 clinical trials
4.7 MArch  

Test study overview

  • 0 views
  • 04 Apr, 2023
  • 2 locations
  • 0 views
  • 14 Mar, 2022
  • 1 location
Fatty Liver  

Fatty liver disease (FLD), also known as hepatic steatosis, is a condition where excess fat builds up in the liver.[1] Often there are no or few symptoms.[1][2] Occasionally there may be tiredness or pain in the upper right side of the abdomen.[1] Complications may include cirrhosis, liver cancer, and esophageal …

hepatitis c
cancer
  • 0 views
  • 14 Mar, 2022
  • 1 location
Demo test Trial  

Test Comment here..

Accepts healthy volunteers
  • 0 views
  • 14 Mar, 2022
  • 6 locations
Preliminary Efficacy and Safety of Apremilast in the Treatment of Acne Conglobata (APACCO) updated  

Apremilast mediates its clinical effect through the cAMP-PKA-NFkappaB pathway which results in a clinical picture changes to a decrease of all signs of inflammation.Due to the NFkappaB mediated chronical inflammation in the pathogenesis of acne conglobata, a treatment with Apremilast seems to be an effective option.In this study, treatment with …

  • 0 views
  • 14 Mar, 2022
  • 4 locations
  • 0 views
  • 14 Mar, 2022
  • 5 locations
  • 0 views
  • 13 Sep, 2023
  • 1 location
Demo Study  

Demo Study 

Online studies
  • 0 views
  • 25 Apr, 2025
  • 1 location
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

  • 0 views
  • 14 Mar, 2022
  • 2 locations
Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI  

The objective of the proposed work is to determine whether administration for 12 months of romosozumab followed by 12 months of denosumab will maintain bone mass at the knee in subjects with subacute SCI compared to 24 months of denosumab administration alone.

  • 0 views
  • 14 Mar, 2022
  • 2 locations